Miruvor
Sign up
The short answer

What studies of oxygen therapy (home oxygen, concentrator) found

11papers on oxygen therapy (home oxygen, concentrator)
115people in 4 studies testing oxygen therapy (home oxygen, concentrator) alone
2randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: D Little or no difference

Based on the strongest evidence, randomised trials and the placebo trial and the randomised trial (very low certainty): 6 findings, all D.

6 outcomes rated · see each below

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 3 findings, all C.

3 outcomes rated · see each below

Preventing long COVID: D Little or no difference

Based on the strongest evidence, compared with another group, not randomised (very low certainty): 2 findings, all D.

2 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, studies found little or no difference with oxygen therapy (home oxygen, concentrator). For ME/CFS, oxygen therapy (home oxygen, concentrator) might help some people, but research can’t show it yet. For preventing long COVID, studies found little or no difference with oxygen therapy (home oxygen, concentrator). If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 11 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Oxygen therapy (home oxygen, concentrator) · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Oxygen therapy (home oxygen, concentrator) · Long COVID is hereOxygen therapy (home oxygen, concentrator) · Preventing long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Cognition (brain fog)2 studies · 42 people received oxygen therapy (home oxygen, concentrator) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 119 people in all; a small benefit can't be ruled out; effect size 0.54 (moderate).

Randomised trials2 studies · 119 people with results

No clear difference in cognition (brain fog).

The evidence is very uncertain about the effect of oxygen therapy (home oxygen, concentrator) on cognition (brain fog) in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • 119 people in all; a small benefit can't be ruled out
  • Effect size 0.54 (moderate)

How big was the difference?

0.54, moderate. The effect size compares oxygen therapy (home oxygen, concentrator) with control.

See the 2 studies
  1. Oxygen supplementation and cognitive function in long-COVID. (2024)

    People in the study
    35 randomised · 21 started · 18 analysed
    Dose
    start flow setting at 3, which could be reduced based on investigator judgment, minimum of 3 hours per day
    Outcome
    Digit Span Backward Total Raw Score, Period 1 post-hoc Digit Span
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Effect of normobaric and hyperbaric hyperoxia treatment on symptoms and cognitive capacities in Long COVID patients: a randomised placebo-controlled, prospective, double-blind trial. (2025)

    People in the study
    101 randomised
    Dose
    100% oxygen at 101.3 kPa (1 atm abs), 10 sessions were given daily over the course of two weeks, with a weekend break in between
    Outcome
    PEBL – DSB Psychology Experiment Building Language (PEBL) – Digit Span Backward (DSB)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Anxiety1 study · 20 people received oxygen therapy (home oxygen, concentrator) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 18 people found no clear difference; a small benefit can't be ruled out; effect size 0.03 (very small).

The randomised trial35 randomised · 21 started · 18 analysed · 2 weeks · start flow setting at 3, which could be reduced based on investigator judgment, minimum of 3 hours per day

No clear difference in anxiety.

The evidence is very uncertain about the effect of oxygen therapy (home oxygen, concentrator) on anxiety in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 18 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.03 (very small)

How big was the difference?

0.03, very small. The effect size compares oxygen therapy (home oxygen, concentrator) with control.

See the 1 study
  1. Oxygen supplementation and cognitive function in long-COVID. (2024)

    People in the study
    35 randomised · 21 started · 18 analysed
    Dose
    start flow setting at 3, which could be reduced based on investigator judgment, minimum of 3 hours per day
    Outcome
    General Anxiety Disorder-7 (GAD-7) Total Score General Anxiety Disorder-7
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
Depression1 study · 20 people received oxygen therapy (home oxygen, concentrator) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 18 people found no clear difference; a small benefit can't be ruled out; effect size 0.30 (small).

The randomised trial35 randomised · 21 started · 18 analysed · 2 weeks · start flow setting at 3, which could be reduced based on investigator judgment, minimum of 3 hours per day

No clear difference in depression.

The evidence is very uncertain about the effect of oxygen therapy (home oxygen, concentrator) on depression in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 18 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.30 (small)

How big was the difference?

0.3, small. The effect size compares oxygen therapy (home oxygen, concentrator) with control.

See the 1 study
  1. Oxygen supplementation and cognitive function in long-COVID. (2024)

    People in the study
    35 randomised · 21 started · 18 analysed
    Dose
    start flow setting at 3, which could be reduced based on investigator judgment, minimum of 3 hours per day
    Outcome
    Patient Health Questionnaire-9 (PHQ9) Total Score Patient Health Questionnaire-9
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    High

Daily life and health overall

Daily functioning2 studies · 42 people received oxygen therapy (home oxygen, concentrator) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 119 people in all; a small benefit can't be ruled out.

Randomised trials2 studies · 119 people with results

No clear difference in daily functioning.

The evidence is very uncertain about the effect of oxygen therapy (home oxygen, concentrator) on daily functioning in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • 119 people in all; a small benefit can't be ruled out

Combination: Deflazacort (oral) + Acebrophylline + Oxygen therapy (home oxygen, concentrator)10 in the study

Insights in the Management of Long COVID-19: Preliminary Observations (2022): Gain in 6MWT, better (not tested).

Shown, not counted: oxygen therapy (home oxygen, concentrator) was given together with other treatments.

See the 2 studies
  1. Oxygen supplementation and cognitive function in long-COVID. (2024)

    People in the study
    35 randomised · 21 started · 18 analysed
    Dose
    start flow setting at 3, which could be reduced based on investigator judgment, minimum of 3 hours per day
    Outcome
    Post-COVID Functional Scale (PCFS) Post-COVID Functional Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Effect of normobaric and hyperbaric hyperoxia treatment on symptoms and cognitive capacities in Long COVID patients: a randomised placebo-controlled, prospective, double-blind trial. (2025)

    People in the study
    101 randomised
    Dose
    100% oxygen at 101.3 kPa (1 atm abs), 10 sessions were given daily over the course of two weeks, with a weekend break in between
    Outcome
    6MWT 6-Minute Walking Test
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Overall symptoms1 study · 22 people received oxygen therapy (home oxygen, concentrator) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 101 people found no clear difference; a small benefit can't be ruled out.

The placebo trial101 randomised · All treatments lasted 95 minutes · 100% oxygen at 101.3 kPa (1 atm abs), 10 sessions were given daily over the course of two weeks, with a weekend break in between

No clear difference in overall symptoms.

The evidence is very uncertain about the effect of oxygen therapy (home oxygen, concentrator) on overall symptoms in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 101 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Effect of normobaric and hyperbaric hyperoxia treatment on symptoms and cognitive capacities in Long COVID patients: a randomised placebo-controlled, prospective, double-blind trial. (2025)

    People in the study
    101 randomised
    Dose
    100% oxygen at 101.3 kPa (1 atm abs), 10 sessions were given daily over the course of two weeks, with a weekend break in between
    Outcome
    C19-YRSm score modified COVID‐19 Yorkshire Rehabilitation Scale (C19-YRSm)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Quality of life1 study · 22 people received oxygen therapy (home oxygen, concentrator) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 101 people found no clear difference; a small benefit can't be ruled out.

The placebo trial101 randomised · All treatments lasted 95 minutes · 100% oxygen at 101.3 kPa (1 atm abs), 10 sessions were given daily over the course of two weeks, with a weekend break in between

No clear difference in quality of life.

The evidence is very uncertain about the effect of oxygen therapy (home oxygen, concentrator) on quality of life in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 101 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Effect of normobaric and hyperbaric hyperoxia treatment on symptoms and cognitive capacities in Long COVID patients: a randomised placebo-controlled, prospective, double-blind trial. (2025)

    People in the study
    101 randomised
    Dose
    100% oxygen at 101.3 kPa (1 atm abs), 10 sessions were given daily over the course of two weeks, with a weekend break in between
    Outcome
    VAS Visual Analogue Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

ME/CFS

Symptoms

Breathlessness1 study · 1 (few people) person received oxygen therapy (home oxygen, concentrator) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 2010 to 2026 · Ninety minutes a day, over six months (few people)

Breathlessness improved.

The evidence is very uncertain about the effect of oxygen therapy (home oxygen, concentrator) on breathlessness in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Home Alone 2020: A First-Person Case Study on Surviving Modern Pandemics and their Aftermath of Illnesses (2026)

    People in the study
    1 in the study
    Dose
    Ninety minutes a day, over six months
    Outcome
    not blue-purple or breathless
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 1 (few people) person received oxygen therapy (home oxygen, concentrator) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 2010 to 2026 · Ninety minutes a day, over six months (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of oxygen therapy (home oxygen, concentrator) on daily functioning in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Home Alone 2020: A First-Person Case Study on Surviving Modern Pandemics and their Aftermath of Illnesses (2026)

    People in the study
    1 in the study
    Dose
    Ninety minutes a day, over six months
    Outcome
    wore a dress reserved for swim days only
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person received oxygen therapy (home oxygen, concentrator) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 2010 to 2026 · Ninety minutes a day, over six months (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of oxygen therapy (home oxygen, concentrator) on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Home Alone 2020: A First-Person Case Study on Surviving Modern Pandemics and their Aftermath of Illnesses (2026)

    People in the study
    1 in the study
    Dose
    Ninety minutes a day, over six months
    Outcome
    brief and remarkable reprieve
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Preventing long COVID

Symptoms

Breathlessness1 study · 72 people received oxygen therapy (home oxygen, concentrator) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised118 in the study · 120 days post-COVID-19

No clear difference in breathlessness.

The evidence is very uncertain about the effect of oxygen therapy (home oxygen, concentrator) on breathlessness later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Impact of Respiratory Support During Hospitalization on Functional Outcomes in Long COVID: A Post-Hoc Analysis of a Prospective Cohort Study. (2024)

    People in the study
    118 in the study
    Dose
    —
    Outcome
    Spirometry function
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Moderate. administered or clinician-rated; assessors blinded: NI
    Selection of the reported result
    Serious. a post-hoc result

Daily life and health overall

Daily functioning1 study · 72 people received oxygen therapy (home oxygen, concentrator) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised118 in the study · 120 days post-COVID-19

No clear difference in daily functioning.

The evidence is very uncertain about the effect of oxygen therapy (home oxygen, concentrator) on daily functioning later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Impact of Respiratory Support During Hospitalization on Functional Outcomes in Long COVID: A Post-Hoc Analysis of a Prospective Cohort Study. (2024)

    People in the study
    118 in the study
    Dose
    —
    Outcome
    6MWT Walk distance (m) six-minute walk test
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Moderate. administered or clinician-rated; assessors blinded: NI
    Selection of the reported result
    Serious. a post-hoc result

Side effects

Stopping because of side effects1 study

All papers

  1. Effect of normobaric and hyperbaric hyperoxia treatment on symptoms and cognitive capacities in Long COVID patients: a randomised placebo-controlled, prospective, double-blind trial.2025 · placebo trial · 101 randomised
    Summary

    Long COVID syndrome is a major health issue, and hyperbaric oxygen therapy (HBOT) has been proposed for treatment. This randomised placebo-controlled, prospective, double-blind trial randomised 101 patients, first recruited among Belgian military personnel by email and later through self-help groups online, into four treatment groups. Patients received 10 sessions of oxygen ‘treatment’ inside a pressure chamber, daily over two weeks. Group A received 100% oxygen at 253 kPa; group B 40% oxygen at 253 kPa; group C 100% oxygen at 101.3 kPa; group D 21% oxygen at 101.3 kPa. All treatments lasted 95 minutes: 15 minutes compression, 70 minutes treatment and 10 minutes decompression. Quality of life symptom scores (VAS, EQ-5D-5L, C19-YRSm), a 6-minute walking test and five neurocognitive tests were given before and after the treatment series; at three months post-treatment a telephone questionnaire probed lasting effects. After treatment, there were no significant differences in subjective symptoms, functional scores and cognitive performance between any groups. The response was variable, with some patients in group D reporting subjective improvement; some scores improved after treatment without a significant inter-group difference. Four patients dropped out because of middle ear barotrauma, two in groups A and B and two in groups C and D. Side effects were significant and mostly related to confinement in a pressure chamber and wearing a mask; middle ear barotrauma occurred in all groups. In total, 101 patients completed the study, of whom 98 were available for three months follow-up; after randomisation, 120 patients were scheduled to start.

  2. Oxygen supplementation and cognitive function in long-COVID.2024 · randomised trial · 35 randomised · 21 started · 18 analysed
    Summary

    The paper reports an exploratory pilot crossover study of a portable oxygen concentrator (POC) for cognitive complaints in long-COVID. Patients were referred from the Montreal Heart Institute and long-COVID clinics in the Montreal area. A total of 35 patients were recruited, and 21 (17 female and 4 male participants) were randomized; 10 were in Sequence 1 and 11 in Sequence 2. POC was used for a minimum of 3 hours per day for 2 weeks, compared with standard of care (Control) for 2 weeks, with a 1-week washout. The study measured MoCA and other neuropsychological tests, PHQ-9, GAD-7, PCFS and oxygen saturation. Overall, there was no relevant improvement of participants’ MoCA total score after a 2-week period under POC vs Control treatments; the mean treatment difference was -0.090 [-1.031, 0.850]. Post-hoc Period 1 analyses showed a MoCA mean treatment difference of 1.705 [0.140, 3.271]. Digit Span backward showed a trend (difference 0.822 [-0.067, 1.711]); PHQ-9 difference was -1.335 [-3.166, 0.495] and GAD-7 difference -0.168 [-2.501, 2.165]. PCFS odds ratio for treatment effect was 1.501 [0.339–6.642]. In Sequence 1, 8 participants completed; in Sequence 2, 10 completed. No serious adverse events occurred during this study. The authors state limitations including a small convenience sample, learning effects on the MoCA, baseline MoCA mostly in the normal range (> 26/30), a short 2-week follow-up, and brain oximetry from two small frontal areas.

  3. Impact of Respiratory Support During Hospitalization on Functional Outcomes in Long COVID: A Post-Hoc Analysis of a Prospective Cohort Study.2024 · compared with another group · 118 in the study
    Summary

    This post hoc analysis of prospectively collected data followed 118 people hospitalized for COVID-19 in the western Brazilian Amazon until 120 days after acute disease. Participants were divided by the respiratory support received during hospitalization: room air (n = 34), non-invasive oxygen therapy (n = 72), and invasive mechanical ventilation (n = 12). At the 120-day follow-up, the study assessed body composition, respiratory muscle strength, pulmonary function, functional capacity, and muscle strength. The authors report no statistically significant differences between groups for spirometry function (p = 0.31), DASI score (p = 0.77), 6MWT (p = 0.43), or handgrip (p = 0.19). At D120, the IMV group had an important loss of body muscle mass and a higher BMM than RAG (p = 0.02). A reduction in MIP (p = 0.01) and MEP (p = 0.02) in the IMV group and OTG group compared with RAG was also observed. No harms or side effects are reported. The authors state limits including a single-center design, unbalanced groups, no functional assessment at hospital discharge, and a relatively short follow-up.

  4. New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago.2022 · no comparison group · 65 in the study
    Summary

    This retrospective study reviewed records of 285 veterans hospitalised for COVID-19 at the Jesse Brown VA Medical Center; 65 were discharged with new domiciliary supplemental oxygen therapy and all 65 were followed for 6 months. There was no comparison group. The paper reports that 46 patients (71%) did not undergo a formal 6-min walk test to re-assess ongoing ambulatory supplemental oxygen requirements. A 6-min walk test was performed in four patients prior to 8 weeks and 15 patients (23%) after 8 weeks from hospital discharge. Domiciliary supplemental oxygen therapy was discontinued in 34 patients (52%) within 8 weeks of discharge, including six within 4 weeks. PASC was reported by 30 patients (46%) for at least 8 weeks after discharge; 43 patients (66%) reported PASC at 8 weeks. From 8 weeks to 6 months, 17 patients (26%) had PASC-related emergency department visits or readmission, and 29 (45%) had PASC reported to their primary care physicians. No deaths were reported within 30 days or from 30 days to 8 weeks; two patients (3%) died during follow-up. The authors state limitations include a single medical centre, small sample size, male predominance and no matched control group.

  5. Home Alone 2020: A First-Person Case Study on Surviving Modern Pandemics and their Aftermath of Illnesses2026 · case report · 1 in the study
    Summary

    This single-person case study reports the author’s ME/CFS course from 2010 to 2026, with no comparison group and no blinding. Treatments included Valtrex (valacyclovir) eight tablets a day throughout 2016; Xue-Fu-Zhu-Yu-Tang; weekly acupuncture for eighteen months; Lomatium dissectum started in July 2019 and taken daily; Oxymatrine (or Equilibrant); X39 phototherapy patches since summer 2020; concentrated oxygen ninety minutes a day over six months; and xylitol nasal spray since winter 2020. The author reports using laboratory results and her own observations, not a validated symptom scale. After only two weeks of Chinese herbs she had a brief and remarkable reprieve. After six weeks of acupuncture she went, in her case, from being bedridden and dying to dancing; after six months of weekly acupuncture she survived a short flight and reported dancing like a twenty year old. Weekly acupuncture over eighteen months revived her, but did not kill the viruses. Lomatium produced an immediate emotional response called a pathogen “die-off” and left her feeling lighter in body and spirit. Patches restored energy; concentrated oxygen coincided with improvements in pre-diabetes, allergies, arthrosis and breathing. Valtrex viral loads never dropped, and eight tablets a day made her very ill. Harms included not tolerating certain herbs or tablets and medication overload, elimination and withdrawal; she never had the Lomatium rash. The authors state the case cannot show causation.

  6. Small airway disease in post-acute COVID-19 syndrome, a non-conventional approach in three years follow-up of a patient with long COVID: a case report.2023 · case report · 1 in the study
    Summary

    This case report described one 60-year-old Hispanic patient who developed severe COVID-19 pneumonia in April 2020, treated at home because the healthcare system was oversaturated, and later had post-acute COVID-19 syndrome. After persistent dyspnea and fatigue, the patient began a bronchodilator twice daily for nine months with low-dose inhaled corticosteroids (160 µg of budesonide and 4.5 µg of formoterol fumarate dihydrate); pulmonary rehabilitation was reinstated. Earlier treatment also included corticosteroids, oxygen via a nasal cannula, and pulmonary rehabilitation. There was no comparison group; outcomes were within-patient before/after measures. At 36 months, restrictive parameters remained stable and DLCO normalized; 6MWT performance was 87% but significant desaturation persisted. CT showed reduced GGO and air trapping, while traction bronchiectasis persisted. FOT and MBW scores improved without normalization. The report also states that oscillometric and MBW measurements improved after a year of follow-up. Side effects and withdrawals were not reported. The authors state that more studies are needed.

  7. Managing Post COVID-19 Patient with Breathlessness.2022 · case report · 1 in the study
    Summary

    This single case report describes a 69-year-old gentleman admitted with RT PCR-confirmed COVID-19 infection and breathlessness, to review the diagnostic approach to post COVID-19 breathlessness. One patient was enrolled and one analysed. He received oral baricitinib and intravenous methylprednisolone for 3 days, then a tapering prednisolone dose starting at 1 mg/kg/day (60 mg/day) with reduction of 10 mg every three days. COPD pharmacotherapy was optimized with early dual bronchodilators; he underwent inpatient pulmonary rehabilitation and was discharged after 22 days of admission with short-term oxygen therapy. He later received home oxygen therapy, a LABA plus LAMA combination inhaler, and outpatient pulmonary rehabilitation. For hospital-acquired pneumonia he received intravenous piperacillin/tazobactam 4.5 g QID. There was no comparison group. Reported findings include improvement of clinical symptoms with radiological resolution of ground glass changes at 3 months post COVID-19 infection, improvement of clinical symptoms and radiological resolution of crazy paving pattern at 3 months, response to antibiotic therapy, discharge after 1 week, and discharge after 22 days of admission with short-term oxygen therapy. One patient had prednisolone stopped due to an active infection, and one patient was treated for hospital-acquired pneumonia. No formal limitations for this case report are stated.

  8. [Fibromyalgia and myalgic encephalomyelitis: The oxygen clue].2016 · case report · 3 in the study
    Summary

    This paper reports three patients with fibromyalgia and myalgic encephalomyelitis who had a severe exacerbation of their symptoms. They were given pure oxygen for a limited time. The paper states that these three patients responded successfully to treatment with pure oxygen for a limited time. No comparison group and no randomisation are reported. The paper does not report the dose, route, setting, follow-up, or how response was measured. No harms, side effects, withdrawals or stopping are reported for the three patients. The authors note that the small number of patients treated and the lack of statistical methodology prevent them from arriving at definitive conclusions. They suggest medical oxygen could be considered an alternative therapy for acute episodes when patients do not respond to other therapeutic strategies, and they suggest designing a future protocol of chronic oxygen therapy. The abstract describes the report as involving a small number of patients and lacking statistical methodology.

  9. Post-COVID Sequelae: From Lung Disease to Long Disease.2023 · combination: given with other treatments · 1 in the study
    Summary

    This case report described one 66-year-old woman with a remote history of reactive airway disease and post-COVID sequelae, or “long Covid.” After a second episode of shortness of breath with a negative COVID test, she was placed on 4L of oxygen by nasal cannula and given prednisone, albuterol, and ipratropium. The text does not report treatment duration. There was no comparison group. The authors report that after treatment with prednisone, albuterol, and ipratropium she experienced symptomatic relief yet again. The next day she showed a marked improvement in her heart rate and respiratory status, and was saturating 96-98% on room air; before treatment she was saturating 88% on room air. She has remained symptom-free since finishing an outpatient prednisone course. Harms, side effects, and withdrawals are not reported. The authors state that the exact mechanism of post-COVID sequelae is not known and that it is unclear why she re-developed shortness of breath after being discharged symptom-free. They conclude that this patient may have been predisposed to a post-COVID sequelae resembling an acute asthma exacerbation, but it is unclear what other risk factors may be contributory in the general population.

  10. Insights in the Management of Long COVID-19: Preliminary Observations2022 · combination: given with other treatments · 10 in the study
    Summary

    This retrospective analysis included 10 patients with long COVID pulmonary sequelae seen at one unit of the outpatient department of Viswanathan Chest Hospital between June 2020 and December 2020. Inclusion required no pre-existing pulmonary disease and available follow-up visits. Five LC-ILD patients with resting hypoxia or exertional desaturation were prescribed systemic steroids (oral deflazacort) plus oral acebrophylline and supplemental oxygen; 2 other LC-ILD patients were prescribed oral acebrophylline only; 2 LC-OAD patients received inhaled budesonide plus inhaled formoterol, with a 7 days course of oral deflazacort; 1 long COVID cough patient received oral acebrophylline. Treatment duration was variable per patient (Table 1). Outcomes included clinical, radiological and functional improvement, resting hypoxia and exertional desaturation, 6MWT distance, mMRC dyspnoea scores, and chest radiograph/HRCT findings. The paper reports improvement in the treated groups: LC-ILD patients responded to oral steroid therapy and showed clinical, radiological as well as functional improvement; LC-OAD patients responded well to inhaled corticosteroids and bronchodilators with symptomatic and functional improvement. Follow-up durations were recorded per patient. The study had no comparison group. Harms and withdrawals were not reported.

  11. Effectiveness of physical, psychological, and alternative interventions for post-COVID-19 condition: a systematic review.2026 · systematic review
    Summary

    This systematic review asked whether supervised physical, psychological and alternative non-pharmacological treatments help adults with post-COVID-19 condition. It included 27 randomized trials with 1,998 participants; trials were supervised and face-to-face and compared interventions with usual care, placebo/sham or active comparators. Interventions included cardiopulmonary rehabilitation, multimodal and unimodal exercise, CBT and lifestyle programmes, neuromodulation, oxygen therapies, acupuncture and balneotherapy. Intervention durations varied. The review reported that cardiopulmonary rehabilitation and multimodal exercise consistently improved cardiorespiratory fitness and walking capacity; CBT and lifestyle adjustments significantly reduced fatigue and subjective concentration complaints. Examples recorded: in 114 participants, CBT lowered CIS-fatigue by a between-group mean difference of −8.8 points (95% CI −11.9 to −5.8); in 70 participants, active HD-tDCS plus rehabilitation lowered MFIS total fatigue by a between-group difference of −14.03 points (95% CI −20.28 to −7.78). Findings for neuromodulation, complementary and oxygen therapies were heterogeneous, often showing no benefit over placebo. For example, HBOT did not produce significantly greater improvements than sham on any primary or secondary outcome. Side effects and withdrawals were not reported in the recorded data. The authors state that the evidence does not support definitive conclusions about the effectiveness of any intervention category.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime